These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8620669)

  • 1. In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite.
    Machinist JM; Kukulka MJ; Bopp BA
    Clin Pharmacokinet; 1995; 29 Suppl 2():34-41. PubMed ID: 8620669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of a new 5-lipoxygenase inhibitor, zileuton, and its inactive N-dehydroxylated metabolite in plasma by high performance liquid chromatography.
    Granneman GR; Braeckman RA; Erdman KA
    Clin Pharmacokinet; 1995; 29 Suppl 2():1-8. PubMed ID: 8620665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers.
    Wong SL; Awni WM; Cavanaugh JH; el-Shourbagy T; Locke CS; Dubé LM
    Clin Pharmacokinet; 1995; 29 Suppl 2():9-21. PubMed ID: 8620676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers.
    Awni WM; Braeckman RA; Cavanaugh JH; Locke CS; Linnen PJ; Granneman GR; Dubé LM
    Clin Pharmacokinet; 1995; 29 Suppl 2():112-24. PubMed ID: 8620667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic interactions between zileuton and prednisone.
    Awni WM; Cavanaugh JH; Tzeng TB; Witt G; Granneman GR; Dubé LM
    Clin Pharmacokinet; 1995; 29 Suppl 2():105-11. PubMed ID: 8620666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of zileuton on theophylline pharmacokinetics.
    Granneman GR; Braeckman RA; Locke CS; Cavanaugh JH; Dubé LM; Awni WM
    Clin Pharmacokinet; 1995; 29 Suppl 2():77-83. PubMed ID: 8620674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.
    Awni WM; Hussein Z; Granneman GR; Patterson KJ; Dubé LM; Cavanaugh JH
    Clin Pharmacokinet; 1995; 29 Suppl 2():67-76. PubMed ID: 8620673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton.
    Awni WM; Cavanaugh JH; Braeckman RA; Chu SY; Patterson KJ; Machinist JM; Granneman GR
    Clin Pharmacokinet; 1995; 29 Suppl 2():49-61. PubMed ID: 8620671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers.
    Awni WM; Braeckman RA; Granneman GR; Witt G; Dubé LM
    Clin Pharmacokinet; 1995; 29 Suppl 2():22-33. PubMed ID: 8620668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193.
    Machinist JM; Mayer MD; Shet MS; Ferrero JL; Rodrigues AD
    Drug Metab Dispos; 1995 Oct; 23(10):1163-74. PubMed ID: 8654206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of food on the pharmacokinetics of zileuton.
    Awni WM; Cavanaugh JH; Witt G; Granneman GR; Dubé LM
    Clin Pharmacokinet; 1995; 29 Suppl 2():62-6. PubMed ID: 8620672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine.
    Awni WM; Cavanaugh JH; Leese P; Kasier J; Cao G; Locke CS; Dube LM
    Eur J Clin Pharmacol; 1997; 52(1):49-54. PubMed ID: 9143867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of zileuton in healthy young and elderly volunteers.
    Braeckman RA; Granneman GR; Locke CS; Machinist JM; Cavannaugh JH; Awni WM
    Clin Pharmacokinet; 1995; 29 Suppl 2():42-8. PubMed ID: 8620670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor.
    Lu P; Schrag ML; Slaughter DE; Raab CE; Shou M; Rodrigues AD
    Drug Metab Dispos; 2003 Nov; 31(11):1352-60. PubMed ID: 14570767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine.
    Awni WM; Braeckman RA; Locke CS; Dubé LM; Granneman GR
    Clin Pharmacokinet; 1995; 29 Suppl 2():98-104. PubMed ID: 8620678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zileuton for asthma.
    Med Lett Drugs Ther; 1997 Feb; 39(995):18-9. PubMed ID: 9057778
    [No Abstract]   [Full Text] [Related]  

  • 17. Quantification of the 5-lipoxygenase inhibitor zileuton in human plasma using high performance liquid chromatography-tandem mass spectrometry.
    Pian P; Labovitz E; Hoffman K; Clavijo CF; Rzasa Lynn R; Galinkin JL; Vinks AA; Malik P; Christians U
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Oct; 937():79-83. PubMed ID: 24029553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug interactions with zileuton.
    Lau R
    Lancet; 1997 May; 349(9063):1479-80. PubMed ID: 9164345
    [No Abstract]   [Full Text] [Related]  

  • 19. Stereoselective plasma protein binding of ibuprofen enantiomers.
    Evans AM; Nation RL; Sansom LN; Bochner F; Somogyi AA
    Eur J Clin Pharmacol; 1989; 36(3):283-90. PubMed ID: 2744069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans.
    Awni WM; Hussein Z; Cavanaugh JH; Granneman GR; Dubé LM
    Clin Pharmacokinet; 1995; 29 Suppl 2():92-7. PubMed ID: 8620677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.